ArticleFrontiers in cell and developmental biology2026
From 5F hematopoietic progenitors to osteoclasts: a scalable human model of osteoclastogenesis.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: Human osteoclast models are essential for studying bone physiology and skeletal disease, yet existing systems are constrained by donor variability and the limited expansion capacity of hematopoietic progenitors. Methods: Conditionally expandable 5F hematopoietic stem and progenitor cells generated by transcription factor reprogramming with HOXA9, ERG, RORA, SOX4, and MYB were differentiated into osteoclasts. Cells were driven through an intermediate monocyte stage using IL three and M CSF, followed by RANKL stimulation to induce osteoclastogenesis. Results: Differentiated cells formed large, multinucleated, TRAP positive osteoclasts displaying F actin ring structures, cathepsin K expression, and strong bone resorptive activity. Gene expression analysis demonstrated marked upregulation of key osteoclast markers including NFATC1, MMP9, CTSK, and CA2. Discussion: By enabling conditional self-renewal at a downstream hematopoietic stage, the 5F platform overcomes key limitations of donor dependent and iPSC derived osteoclast models. This scalable and cytokine driven system provides a reproducible and standardized human osteoclast model suitable for studies of osteoclast biology, bone remodeling, and biomaterial interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.